GSK3β mediates renal response to vasopressin by modulating adenylate cyclase activity

Journal of the American Society of Nephrology

Volumn 21, Issue 3, 2010, Pages 428-437

  Rao, Reena ^a   Patel, Satish ^b   Hao, Chuanming ^a   Woodgett, James ^b   Harris, Raymond ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; AQUAPORIN 2; ARGIPRESSIN; CYCLIC AMP; GLYCOGEN SYNTHASE KINASE 3BETA; VASOPRESSIN DERIVATIVE; ADENYLATE CYCLASE 3; ADENYLYL CYCLASE 6; ANTIDIURETIC AGENT; AQP2 PROTEIN, MOUSE; ARGIPRESSIN[1 DEAMINO]; FORSKOLIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE DELETION; KIDNEY COLLECTING TUBULE; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; POLYURIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; WATER DEPRIVATION; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DRUG EFFECT; ELECTROLYTE BALANCE; ENZYMOLOGY; GENETICS; KIDNEY CONCENTRATING CAPACITY; MALE; METABOLISM; MOUSE MUTANT; PHYSIOLOGY;

ADENYLATE CYCLASE; ANIMALS; ANTIDIURETIC AGENTS; AQUAPORIN 2; CELLS, CULTURED; CYCLIC AMP; DEAMINO ARGININE VASOPRESSIN; FEMALE; FORSKOLIN; GLYCOGEN SYNTHASE KINASE 3; KIDNEY CONCENTRATING ABILITY; KIDNEY TUBULES, COLLECTING; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RNA, MESSENGER; WATER DEPRIVATION; WATER-ELECTROLYTE BALANCE;

EID: 77949909272     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2009060672     Document Type: Article

References (56)

1. Mukai F, Ishiguro K, Sano Y, Fujita SC: Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. J Neurochem 81: 1073-1083, 2002
2. Doble BW, Woodgett JR: GSK-3: Tricks of the trade for a multi-tasking kinase. J Cell Sci 116: 1175-1186, 2003
3. Woodgett JR: Physiological roles of glycogen synthase kinase-3: Potential as a therapeutic target for diabetes and other disorders. Curr Drug Targets Immune Endocr Metabol Disord 3: 281-290, 2003
4. MacAulay K, Doble BW, Patel S, Hansotia T, Sinclair EM, Drucker DJ, Nagy A, Woodgett JR: Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. Cell Metab 6: 329-337, 2007
5. Patel S, Doble BW, MacAulay K, Sinclair EM, Drucker DJ, Woodgett JR: Tissue-specific role of glycogen synthase kinase 3beta in glucose homeostasis and insulin action. Mol Cell Biol 28: 6314-6328, 2008
6. Kerkela R, Kockeritz L, Macaulay K, Zhou J, Doble BW, Beahm C, Greytak S, Woulfe K, Trivedi CM, Woodgett JR, Epstein JA, Force T, Huggins GS: Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J Clin Invest 118: 3609-3618, 2008
7. Nielsen J, Hoffert JD, Knepper MA, Agre P, Nielsen S, Fenton RA: Proteomic analysis of lithium-induced nephrogenic diabetes insipidus: mechanisms for aquaporin 2 down-regulation and cellular proliferation. Proc Natl Acad Sci USA 105: 3634-3639, 2008
8. Rao R, Zhang MZ, Zhao M, Cai H, Harris RC, Breyer MD, Hao CM: Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria. Am J Physiol Renal Physiol 288: F642-F649, 2005
9. Woodgett J.R., Force T. Unique and overlapping functions of GSK-3 isoforms in cellular differentiation, proliferation, and cardiovascular development, J Biol Chem, 284, 9643-9647 2009.
10. Klein PS, Melton DA: A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93: 8455-8459, 1996
11. Bendz H, Sjodin I, Aurell M: Renal function on and off lithium in patients treated with lithium for 15 years or more. A controlled, prospective lithium-withdrawal study. Nephrol Dial Transplant 11: 457-460, 1996
12. Boton R, Gaviria M, Batlle DC: Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 10: 329-345, 1987
13. Livingstone C, Rampes H: Lithium: A review of its metabolic adverse effects. J Psychopharmacol 20: 347-355, 2006
14. Nielsen S, Frokiaer J, Marples D, Kwon TH, Agre P, Knepper MA: Aquaporins in the kidney: From molecules to medicine. Physiol Rev 82: 205-244, 2002
15. Matsumura Y, Uchida S, Rai T, Sasaki S, Marumo F: Transcriptiona regulation of aquaporin-2 water channel gene by cAMP. J Am Soc Nephrol 8: 861-867, 1997
16. Umenishi F, Narikiyo T, Vandewalle A, Schrier RW: cAMP regulates vasopressin-induced AQP2 expression via protein kinase A-indepen-dent pathway. Biochim Biophys Acta 1758: 1100-1105, 2006
17. Yasui M, Zelenin SM, Celsi G, Aperia A: Adenylate cyclase-coupled vasopressin receptor activates AQP2 promoter via a dual effect on CRE and AP1 elements. Am J Physiol 272: F443-F450, 1997
18. Fushimi K, Sasaki S, Marumo F: Phosphorylation of serine 256 is required for cAMP-dependent regulatory exocytosis of the aquaporin-2 water channel. J Biol Chem 272: 14800-14804, 1997
19. Christensen BM, Marples D, Kim YH, Wang W, Frokiaer J, Nielsen S: Changes in cellular composition of kidney collecting duct cells in rats with lithium-induced NDI. Am J Physiol Cell Physiol 286: C952-C964, 2004
20. Kwon TH, Laursen UH, Marples D, Maunsbach AB, Knepper MA, Frokiaer J, Nielsen S: Altered expression of renal AQPs and Na(+) transporters in rats with lithium-induced NDI. Am J Physiol Renal Physiol 279: F552-F564, 2000
21. Marples D, Christensen S, Christensen EI, Ottosen PD, Nielsen S: Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest 95: 1838-1845, 1995
22. Goldberg H, Clayman P, Skorecki K: Mechanism of Li inhibition of vasopressin-sensitive adenylate cyclase in cultured renal epithelia cells. Am J Physiol 255: F995-F1002, 1988
23. Jackson BA, Edwards RM, Dousa TP: Lithium-induced polyuria: Effect of lithium on adenylate cyclase and adenosine 3',5'-monophosphate phosphodiesterase in medullary ascending limb of Henle's loop and in medullary collecting tubules. Endocrinology 107: 1693-1698, 1980
24. Yamaki M, Kusano E, Tetsuka T, Takeda S, Homma S, Murayama N, Asano Y: Cellular mechanism of lithium-induced nephrogenic diabetes insipidus in rats. Am J Physiol 261: F505-F511, 1991
25. Christensen S, Kusano E, Yusufi AN, Murayama N, Dousa TP: Pathogenesis of nephrogenic diabetes insipidus due to chronic administration of lithium in rats. J Clin Invest 75: 1869-1879, 1985
26. Timmer RT, Sands JM: Lithium intoxication. J Am Soc Nephrol 10: 666-674, 1999
27. Hebert RL: Cellular signalling of PGE2 and its selective receptor ana-logue sulprostone in rabbit cortical collecting duct. Prostaglandins Leukot Essent Fatty Acids 51: 147-155, 1994
28. Hebert RL, Jacobson HR, Fredin D, Breyer MD: Evidence that separate PGE2 receptors modulate water and sodium transport in rabbit cortical collecting duct. Am J Physiol 265: F643-F650,1993
29. Hasler U, Mordasini D, Bens M, Bianchi M, Cluzeaud F, Rousselot M, Vandewalle A, Feraille E, Martin PY: Long term regulation of aquaporin-2 expression in vasopressin-responsive renal collecting duct principal cells. J Biol Chem 277: 10379-10386, 2002 (Pubitemid 34968157)
30. Li Y, Shaw S, Kamsteeg EJ, Vandewalle A, Deen PM: Development of lithium-induced nephrogenic diabetes insipidus is dissociated from adenylyl cyclase activity. J Am Soc Nephrol 17: 1063-1072, 2006
31. Rao AS, Kremenevskaja N, Resch J, Brabant G: Lithium stimulates proliferation in cultured thyrocytes by activating Wnt/beta-catenin signalling. Eur J Endocrinol 153: 929-938, 2005
32. Salas TR, Reddy SA, Clifford JL, Davis RJ, Kikuchi A, Lippman SM, Menter DG: Alleviating the suppression of glycogen synthase kinase-3beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei. J Biol Chem 278: 41338-41346, 2003
33. Christensen BM, Kim YH, Kwon TH, Nielsen S: Lithium treatment induces a marked proliferation of primarily principal cells in rat kidney inner medullary collecting duct. Am J Physiol Renal Physiol 291: F39-F48, 2006
34. Kim YH, Kwon TH, Christensen BM, Nielsen J, Wall SM, Madsen KM, Frokiaer J, Nielsen S: Altered expression of renal acid-base transporters in rats with lithium-induced NDI. Am J Physiol Renal Physiol 285: F1244-F1257, 2003 (Pubitemid 37421060)
35. Verbalis JG: Vasopressin V2 receptor antagonists. J Mol Endocrinol 29: 1-9, 2002
36. Sasaki S, Noda Y: Aquaporin-2 protein dynamics within the cell. Curr Opin Nephrol Hypertens 16: 348-352, 2007
37. Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, Nielsen S: Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol 288: F1053-F1068, 2005
38. Jia Z, Wang H, Yang T: Mice lacking mPGES-1 are resistant to lithium-induced polyuria. Am J Physiol Renal Physiol 297: 1689-1696, 2009
39. Hasler U, Nielsen S, Feraille E, Martin PY: Posttranscriptional control of aquaporin-2 abundance by vasopressin in renal collecting duct principal cells. Am J Physiol Renal Physiol 290: F177-F187, 2006
40. Marples D, Frokiaer J, Knepper MA, Nielsen S: Disordered water channel expression and distribution in acquired nephrogenic diabetes insipidus. Proc Assoc Am Physicians 110: 401-406, 1998
41. Promeneur D, Kwon TH, Frokiaer J, Knepper MA, Nielsen S: Vaso-pressin V(2)-receptor-dependent regulation of AQP2 expression in Brattleboro rats. Am J Physiol Renal Physiol 279: F370-F382, 2000
42. Walker RJ, Weggery S, Bedford JJ, McDonald FJ, Ellis G, Leader JP: Lithium-induced reduction in urinary concentrating ability and urinary aquaporin 2 (AQP2) excretion in healthy volunteers. Kidney Int 67: 291-294, 2005
43. Cogan E, Abramow M: Inhibition by lithium of the hydroosmotic action of vasopressin in the isolated perfused cortical collecting tubule of the rabbit. J Clin Invest 77: 1507-1514, 1986
44. Cogan E, Svoboda M, Abramow M: Mechanisms of lithium-vasopres-sin interaction in rabbit cortical collecting tubule. Am J Physiol 252: F1080-F1087, 1987
45. Hozawa S, Holtzman EJ, Ausiello DA: cAMP motifs regulating transcription in the aquaporin 2 gene. Am J Physiol 270: C1695-C1702, 1996
46. Frokiaer J, Marples D, Valtin H, Morris JF, Knepper MA, Nielsen S: Low aquaporin-2 levels in polyuric DI +/+ severe mice with constitutively high cAMP-phosphodiesterase activity. Am J Physiol 276: F179-F190, 1999
47. Hoffert JD, Chou CL, Fenton RA, Knepper MA: Calmodulin is required for vasopressin-stimulated increase in cyclic AMP production in inner medullary collecting duct. J Biol Chem 280: 13624-13630, 2005
48. Robben JH, Knoers NV, Deen PM: Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 291: F257-F270, 2006
49. Procino G, Carmosino M, Tamma G, Gouraud S, Laera A, Riccardi D, Svelto M, Valenti G: Extracellular calcium antagonizes forskolin-in-duced aquaporin 2 trafficking in collecting duct cells. Kidney Int 66: 2245-2255, 2004
50. Sugawara M, Hashimoto K, Ota Z: Involvement of prostaglandin E2, cAMP, and vasopressin in lithium-induced polyuria. Am J Physiol 254: R863-R869, 1988
51. Nielsen J, Kwon TH, Christensen BM, Frokiaer J, Nielsen S: Dysregu-ation of renal aquaporins and epithelial sodium channel in lithium-induced nephrogenic diabetes insipidus. Semin Nephrol 28: 227-244, 2008
52. Yu J, Carroll TJ, McMahon AP: Sonic hedgehog regulates proliferation and differentiation of mesenchymal cells in the mouse metanephric kidney. Development 129: 5301-5312, 2002
53. Rao R, Redha R, Macias-Perez I, Su Y, Hao C, Zent R, Breyer MD, Pozzi A: Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. J Biol Chem 282: 16959-16968, 2007
54. Kim SW, Jeon YS, Lee JU, Kang DG, Kook H, Ahn KY, Kim SZ, Cho KW, Kim NH, Han JS, Choi KC: Diminished adenylate cyclase activity and aquaporin 2 expression in acute renal failure rats. Kidney Int 57: 1643-1650, 2000
55. Salomon Y, Londos C, Rodbell M: A highly sensitive adenylate cyclase assay. Anal Biochem 58: 541-548, 1974
56. Kelly JJ, Stevens T, Thompson J, Seifert R: Adenylyl and guanylyl cyclase assays. Curr Protoc Pharmacol 2.2.1-2.2.21, 2005